VeriLuce Therapeutics is an R&D/early-stage drug development company currently designing and developing novel small molecules targeting two chemokine receptors in dual antagonistic mode. The objective is to target such receptors within the tumor microenvironment to modulate the immune system to activate tumor-killing immune cells and suppress tumor-enhancing immune cells. VeriLuce is in the process of optimizing its small molecules in terms of chemistry design and binding affinity. Its best compound to date has shown promising results in a 3D Tumor Cell Death Assay against Triple Negative Breast Cancer cells.

Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


33 in total